Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting...
Data demonstrate progress in each of its MSC-derived programs MELVILLE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq:...
Collaboration establishes an independent clinical validation pathway, expands access to influential physician networks, and strengthens the foundation for possible broad commercial growth across professional,...
Partnership to drive brand architecture, go-to-market execution, and global launch of the Company’s product portfolio bridging biotechnology and premium skincare MELVILLE, N.Y., April 07, 2026...
Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal...
New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company’s proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th...
Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy MELVILLE, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- BioRestorative...
Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation continues...
GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic...
MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator...